Melanotan II: I Went Through the Whole Paper Trail. Here’s My Honest Verdict

I didn’t inject anything for this one. Let’s get that out of the way first, because a lot of what gets written about Melanotan II reads like a testimonial, and I’m not in the business of testimonials. What I did instead is the thing I do with any product that makes big claims: I pulled the actual studies, read the case reports, and checked whether the marketing matches the paper trail. Spoiler, it partly does. That’s rarer than you’d think, and it’s also the most alarming part of this whole review.

Melanotan II is a lab-built copy of a hormone your body already makes, alpha-melanocyte-stimulating hormone (alpha-MSH), which tells pigment cells to darken. Chemists at the University of Arizona engineered it back in the 1980s and 90s to hit that pigment receptor harder and longer than the natural hormone does. It succeeded. The problem is it doesn’t hit just that one receptor. It also fires the receptors tied to erections and appetite, because those receptors are close cousins in the same family. So you get a tanning drug that also, reliably, gives men erections and kills appetite. Not a side effect. Just what the molecule does when you switch on the whole switchboard instead of one switch.

One thing worth clearing up before I grade anything: there are two “melanotans” and they get conflated on purpose. Melanotan I, now called afamelanotide, is the more selective, better-behaved sibling. It actually finished trials and got approved, but only for a rare genetic sun-sensitivity disease, and only as a clinician-placed implant (Kim and Garnock-Jones, 2016). Melanotan II, the stuff sold in gray-market vials for cosmetic tanning, never finished development and isn’t approved anywhere. Sellers lean on the family resemblance to borrow legitimacy it hasn’t earned.

What it claims to do, and my honest read on each one

Three pitches get made for this compound: it tans you fast, it boosts your sex drive, it kills your appetite. I graded each against the actual human data instead of the forum consensus.

Tanning: pass, no asterisk on efficacy, big asterisk on safety. A 1996 pilot study gave the peptide to healthy volunteers and got real, visible tanning and increased melanin, calling it a superpotent tanning agent. Same study logged the cost plainly: nausea and facial flushing were the most common complaints (Dorr et al., 1996). A 2004 follow-up paired it with UV light and confirmed the darkening again (Dorr et al., 2004). So credit where it’s due, this thing tans. What it doesn’t do is undo the sun damage from the UV exposure most users pair it with. A tan is a tan. It isn’t a shield.

Libido and erections: also pass, and honestly the strongest data point in the whole file. A placebo-controlled study found erections in 17 of 20 men and increased self-reported desire, and this family of molecules later spun off an actual approved erectile-dysfunction drug (Wessells et al., 2000). But read the fine print: nausea and yawning showed up constantly, and pushing the dose higher pushed the nausea into “severe” territory for a real chunk of subjects. You don’t get the erection without the queasiness. They’re wired to the same receptor, so you can’t order one without the other.

Appetite suppression: incomplete, don’t grade it as a win. It’s a plausible mechanism, sure, people report it anecdotally all the time, but there’s no controlled human trial establishing it as a real or safe weight-loss tool with this specific compound. File it under “known biology,” not “proven benefit.”

Where it holds up, and where it falls apart

Here’s my problem with this drug, and it’s not the tanning or the libido claims, both of which the data back up more than I expected going in. It’s everything after those two studies. The rest of the published literature isn’t trials of benefit. It’s case reports of people getting hurt.

A 20-year-old woman with fair skin developed melanoma after using Melanotan II to deepen a sunbed tan, and the authors’ takeaway was blunt: warn at-risk patients about this (Hjuler and Lorentzen, 2014). Stimulating pigment cells while chasing UV exposure is exactly the combination that makes dermatologists nervous, and it’s why anyone using this needs their moles watched.

A man ended up with systemic toxicity and rhabdomyolysis, muscle breakdown severe enough to threaten his kidneys, after injecting it (Nelson et al., 2012). Men have also shown up with priapism, a prolonged, painful erection that’s a genuine urological emergency. One case report has the kind of title that tells you everything: “a hard-earned tan” (Dreyer et al., 2019).

A 2017 review tied all this together, flagging mole changes, the theoretical melanoma link, and the basic problem of injecting an unlicensed product of unknown quality (Habbema et al., 2017). A 2009 BMJ editorial had already named the structural issue years earlier: this stuff gets sold online as an unlicensed substance, completely outside any medical oversight (Evans-Brown et al., 2009).

So my scorecard looks like this. Tans skin: yes. Boosts libido: yes. Comes with nausea baked in: yes. Reliably safe over the long term in healthy users: nobody has ever actually checked that in a real trial, and the case reports we do have are not reassuring.

About the dosing numbers you’ll see online

I want to be straight with you here: there is no official dose. None. No regulator has signed off on a Melanotan II protocol, so every number you see on a forum, the “load with a few hundred micrograms daily, then taper to maintenance,” comes from user habit and old research settings, not from anyone with the authority to say it’s safe. Reading those numbers is reading a folk record, not a prescription.

Two things matter more than the actual microgram figures. First, the powder sold by research-chemical vendors comes with zero guarantee of what’s actually in the vial. A “500 microgram” dose from a mislabeled or underdosed batch isn’t the dose you think it is. Second, the trials themselves showed the nausea gets worse as the dose climbs (Wessells et al., 2000). Chasing a faster tan by upping the dose is chasing worse side effects, documented in the same study that documented the benefit.

The regulatory contrast that tells you everything

It’s worth asking why one melanocortin drug made it to market and the other didn’t, because the answer is basically the whole review in miniature. Afamelanotide, the approved cousin, is more selective and was built for a specific, rare, painful disease. It’s delivered by a clinician as a controlled implant and went through actual trials (Kim and Garnock-Jones, 2016). That’s the bar. A defined disease, a controlled product, real oversight. Melanotan II, sold in unmarked vials for cosmetic tanning, has never come close to clearing it. Keep that in mind any time a seller implies the two are basically the same drug.

Where I land on supervision

If the actual problem here is a compound with no quality control sold by people who don’t ask about your health, then the one variable that changes the risk equation is whether a licensed professional is standing between you and the syringe. That’s not a marketing point, it’s the honest difference between the gray market and a clinical one. FormBlends is one outfit that handles Melanotan II inside an actual clinical relationship: a physician reviews your history first, a licensed compounding pharmacy prepares what gets dispensed, and there’s someone accountable afterward.

I want to be precise about what that buys you, because it doesn’t buy you a proven or risk-free product. Nothing on the current evidence gets you that. What it buys is a licensed person checking your moles before you start stimulating pigment cells, checking your blood pressure, telling you honestly that the long-term data are thin, and, for some people, telling you not to bother at all. Compounded medications are prepared by licensed pharmacies for an individual and aren’t FDA-approved products themselves. For a compound with a safety record built out of case reports, that screening step is the real value, not a faster tan.

My verdict

Melanotan II does two of the three things people claim it does, and does them for real, documented in human trials going back to the 90s. It also comes bundled with nausea that scales with dose, and the rest of its medical footprint is a string of case reports, melanoma, rhabdomyolysis, priapism, that should give anyone pause. Nobody has run the long-term safety trial in healthy cosmetic users. Nobody can tell you it’s safe, because that trial doesn’t exist.

I’m not telling you to panic. I’m telling you to read this the way I read any product claim: check what’s actually proven, note what isn’t, and don’t let anyone sell you certainty the evidence doesn’t have. If you’re going anywhere near this compound, put a licensed professional between you and the vial. That’s not caution for its own sake. That’s just what the record actually supports.

A few common questions

Is Melanotan II the same as the approved Melanotan I implant?

No. Melanotan I is afamelanotide, a more selective compound approved for the rare light-sensitivity condition erythropoietic protoporphyria, delivered as a clinician-placed implant. Melanotan II is a different, less selective peptide that never finished development and isn’t approved anywhere for human use. The shared name is the source of a lot of marketing sleight of hand, and only the first molecule has earned any approval.

Does Melanotan II actually work as a tanning agent?

Yes, and this is the one claim I’d stand behind without hedging. A 1996 phase-I study documented real melanin increase and visible tanning in healthy volunteers, and a 2004 follow-up confirmed skin darkening when paired with UV exposure. The tan is genuine. What it isn’t is safe by extension, since stimulating pigment cells doesn’t undo UV damage.

Why does a tanning peptide cause erections and kill your appetite?

Because it’s not selective. It switches on several melanocortin receptors at once, including the pigment receptor and the ones tied to sexual function and appetite. Spontaneous erections and reduced hunger aren’t accidents, they’re what happens when you activate that whole receptor family at once. It’s also why nausea tends to show up right alongside the sexual effect.

What are the most serious risks documented in the medical literature?

Published case reports include melanoma in a young fair-skinned user, systemic toxicity with rhabdomyolysis (muscle breakdown that can damage the kidneys), and priapism, a prolonged painful erection that counts as a medical emergency. Reviews have also flagged mole changes and the quality risks of injecting an unlicensed product. Nausea and facial flushing are the most common effects logged in the early trials.

Why is purity such a big deal with gray-market Melanotan II?

Because the powder sold by research-chemical vendors comes with no guarantee of what’s actually in it, identity, content, or sterility. A vial labeled at a certain dose could be underdosed, mislabeled, or contaminated, so what you think you’re injecting may not match what’s actually in there. That’s stacked on top of the compound’s own risks, which is exactly why having a licensed pharmacy handle preparation matters more than any dosing trick you’ll find online.

Does melanotan II work without sun exposure?

It does stimulate melanin on its own, but most users and researchers report a noticeably better result when some UV gets added, even just ordinary daylight. The peptide switches melanocytes on, but light still drives the full tanning response. Skip the UV entirely and results tend to come out modest and patchy. Combining the two to chase a deeper tan brings its own skin-damage risk.

Can melanotan II actually change your eye color?

There’s no reliable clinical evidence for that. What gets reported anecdotally is darkening of existing moles or nevi near the eyes, not an actual iris color change. Any darkening of moles around the eyes should get checked by a dermatologist promptly, since changing moles is one of the documented safety flags in the literature.

How much melanotan II do people typically use, and is there a safe dose?

There’s no approved guideline because this compound has never cleared trials or gotten regulatory approval anywhere. Gray-market sources pass around dose ranges, but those come from forums, not controlled research. The doses that produce tanning overlap with the doses that produce nausea, erections, and blood-pressure changes. There’s genuinely no established safe line, and self-dosing unverified powder just adds more risk on top.

Where do people actually buy melanotan II, and what are the risks of those sources?

Mostly through online gray-market vendors selling lyophilized powder, which sits in a legal gray zone in a lot of countries and is flat-out banned for human use in others, including the UK and Australia. Independent lab tests of these products have repeatedly turned up dosing errors and contamination. For people in a position to have a physician supervise peptide use through a licensed compounding pharmacy, an outfit like FormBlends is a more accountable route, but the compound itself remains unapproved no matter who supplies it.

References (primary sources)

1. Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences, 1996. PMID 8637402.
2. Dorr RT, Ertl G, Levine N, Brooks C, Bangert JL, Powell MB, et al. Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers. Archives of Dermatology, 2004. PMID 15262693.
3. Wessells H, Levine N, Hadley ME, Dorr R, Hruby V. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. International Journal of Impotence Research, 2000. PMID 11035391.
4. Hjuler KF, Lorentzen HF. Melanoma associated with the use of melanotan-II. Dermatology, 2014. PMID 24355990.
5. Nelson ME, Bryant SM, Aks SE. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clinical Toxicology, 2012. PMID 23121206.
6. Dreyer BA, Amer T, Fraser M. Melanotan-induced priapism: a hard-earned tan. BMJ Case Reports, 2019. PMID 30796078.
7. Habbema L, Halk AB, Neumann M, Bergman W. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. International Journal of Dermatology, 2017. PMID 28266027.
8. Evans-Brown M, Dawson RT, Chandler M, McVeigh J. Use of melanotan I and II in the general population. BMJ, 2009. PMID 19224885.
9. Kim ES, Garnock-Jones KP. Afamelanotide: A Review in Erythropoietic Protoporphyria. American Journal of Clinical Dermatology, 2016. PMID 26979527.